Twenty-four-hour heart rate lowering with ivabradine in chronic heart failure: Insights from the SHIFT Holter substudy

European Journal of Heart Failure

Volumn 17, Issue 5, 2015, Pages 518-526

  Böhm, Michael ^a   Borer, Jeffrey S ^b   Camm, John ^c   Ford, Ian ^d   Lloyd, Suzanne M ^d   Komajda, Michel ^e   Tavazzi, Luigi ^f   Talajic, Mario ^g   Lainscak, Mitja ^h   Reil, Jan Christian ^a   Ukena, Christian ^a   Swedberg, Karl ⁱ  

^a SAARLAND UNIVERSITY   (Germany)

^b Schiavone Institute for Cardiovascular Translational Research   (United States)

^c ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^d UNIVERSITY OF GLASGOW   (United Kingdom)

^e PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^f MARIA CECILIA HOSPITAL   (Italy)

^g Montreal Rehabilitation Institute   (Canada)

^h UNIVERSITY CLINIC OF RESPIRATORY AND ALLERGIC DISEASES   (Slovenia)

ⁱ UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

24 h heart rate; Heart failure; Heart rate; Ivabradine; Left ventricular dysfunction; Night time heart rate

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IVABRADINE; BENZAZEPINE DERIVATIVE; CARDIOVASCULAR AGENT;

ADULT; ARTICLE; ATRIAL FIBRILLATION; ATRIOVENTRICULAR BLOCK; BRADYCARDIA; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG SAFETY; FEMALE; HEART RATE TURBULENCE; HEART RATE VARIABILITY; HEART RHYTHM; HEART SUPRAVENTRICULAR ARRHYTHMIA; HEART VENTRICLE ARRHYTHMIA; HOLTER MONITORING; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RR INTERVAL; SUPRAVENTRICULAR TACHYCARDIA; SYSTOLIC HEART FAILURE; AGED; DRUG EFFECTS; ELECTROCARDIOGRAPHY; HEART FAILURE, SYSTOLIC; HEART RATE; PROCEDURES; PROSPECTIVE STUDY;

AGED; BENZAZEPINES; CARDIOVASCULAR AGENTS; ELECTROCARDIOGRAPHY, AMBULATORY; FEMALE; HEART FAILURE, SYSTOLIC; HEART RATE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 84928625380     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1002/ejhf.258     Document Type: Article

References (35)

1. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med 1991; 325: 293-302.
2. Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F, Smith R, Dunkman WB, Loeb H, Wong M,. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991; 325: 303-310.
3. Dunlay SM, Redfield MM, Weston SA, Therneau TM, Hall LK, Shah ND, Roger VL,. Hospitalizations after heart failure diagnosis a community perspective. J Am Coll Cardiol 2009; 54: 1695-1702.
4. Haldeman GA, Croft JB, Giles WH, Rashidee A,. Hospitalization of patients with heart failure: National Hospital Discharge Survey, 1985 to 1995. Am Heart J 1999; 137: 352-360.
5. Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls MG, Richards AM,. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 2000; 355: 1126-1130.
6. Heart rate variability for risk stratification of life-threatening arrhythmias. American College of Cardiology Cardiovascular Technology Assessment Committee. J Am Coll Cardiol 1993; 22: 948-950.
7. Nolan J, Batin PD, Andrews R, Lindsay SJ, Brooksby P, Mullen M, Baig W, Flapan AD, Cowley A, Prescott RJ, Neilson JM, Fox KA,. Prospective study of heart rate variability and mortality in chronic heart failure: results of the United Kingdom heart failure evaluation and assessment of risk trial (UK-heart). Circulation 1998; 98: 1510-1516.
8. Heart rate variability: standards of measurement, physiological interpretation and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Circulation 1996; 93: 1043-1065.
9. Fox K, Ford I, Steg PG, Tendera M, Ferrari R,. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet 2008; 372: 807-816.
10. Fox K, Ford I, Steg PG, Tendera M, Robertson M, Ferrari R,. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet 2008; 372: 817-821.
11. Johansen CD, Olsen RH, Pedersen LR, Kumarathurai P, Mouridsen MR, Binici Z, Intzilakis T, Kober L, Sajadieh A,. Resting, night-time, and 24 h heart rate as markers of cardiovascular risk in middle-aged and elderly men and women with no apparent heart disease. Eur Heart J 2013; 34: 1732-1739.
12. Shen MJ, Zipes DP,. Role of the autonomic nervous system in modulating cardiac arrhythmias. Circ Res 2014; 114: 1004-1021.
13. Bullinga JR, Alharethi R, Schram MS, Bristow MR, Gilbert EM,. Changes in heart rate variability are correlated to hemodynamic improvement with chronic carvedilol therapy in heart failure. J Card Fail 2005; 11: 693-699.
14. Flapan AD, Nolan J, Neilson JM, Ewing DJ,. Effect of captopril on cardiac parasympathetic activity in chronic cardiac failure secondary to coronary artery disease. Am J Cardiol 1992; 69: 532-535.
15. Goldsmith RL, Bigger JT, Bloomfield DM, Krum H, Steinman RC, Sackner-Bernstein J, Packer M,. Long-term carvedilol therapy increases parasympathetic nervous system activity in chronic congestive heart failure. Am J Cardiol 1997; 80: 1101-1104.
16. Borer JS, Fox K, Jaillon P, Lerebours G,. Antianginal and antiischemic effects of ivabradine, an I(f) inhibitor, in stable angina: a randomized, double-blind, multicentered, placebo-controlled trial. Circulation 2003; 107: 817-823.
17. Tardif JC, Ford I, Tendera M, Bourassa MG, Fox K,. Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J 2005; 26: 2529-2536.
18. Swedberg K, Komajda M, Böhm M, Borer J, Ford I, Dubost-Brama A, Lerebours G, Tavazzi L,. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled trial. Lancet 2010; 376: 875-885.
19. DiFrancesco D., The contribution of the 'pacemaker' current (if) to generation of spontaneous activity in rabbit sino-atrial node myocytes. J Physiol 1991; 434: 23-40.
20. DiFrancesco D, Camm AJ,. Heart rate lowering by specific and selective If current inhibition with ivabradine. A new therapeutic perspective in cardiovascular disease. Drugs 2004; 64: 1757-1765.
21. Bohm M, Swedberg K, Komajda M, Borer JS, Ford I, Dubost-Brama A, Lerebours G, Tavazzi L,. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet 2010; 376: 886-894.
22. Bohm M, Borer J, Ford I, Gonzalez-Juanatey JR, Komajda M, Lopez-Sendon J, Reil JC, Swedberg K, Tavazzi L,. Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study. Clin Res Cardiol 2013; 102: 11-22.
23. Ben-Dov IZ, Kark JD, Ben-Ishay D, Mekler J, Ben-Arie L, Bursztyn M,. Blunted heart rate dip during sleep and all-cause mortality. Arch Intern Med 2007; 167: 2116-2121.
24. Palatini P, Thijs L, Staessen JA, Fagard RH, Bulpitt CJ, Clement DL, de Leeuw PW, Jaaskivi M, Leonetti G, Nachev C, O'Brien ET, Parati G, Rodicio JL, Roman E, Sarti C, Tuomilehto J,. Predictive value of clinic and ambulatory heart rate for mortality in elderly subjects with systolic hypertension. Arch Intern Med 2002; 162: 2313-2321.
25. Hozawa A, Inoue R, Ohkubo T, Kikuya M, Metoki H, Asayama K, Hara A, Hirose T, Kanno A, Obara T, Hoshi H, Hashimoto J, Totsune K, Satoh H, Imai Y,. Predictive value of ambulatory heart rate in the Japanese general population: the Ohasama study. J Hypertens 2008; 26: 1571-1576.
26. Palatini P, Reboldi G, Beilin LJ, Eguchi K, Imai Y, Kario K, Ohkubo T, Pierdomenico SD, Saladini F, Schwartz JE, Wing L, Verdecchia P,. Predictive value of night-time heart rate for cardiovascular events in hypertension. The ABP-International study. Int J Cardiol 2013; 168: 1490-1495.
27. Tardif JC, O'Meara E, Komajda M, Bohm M, Borer JS, Ford I, Tavazzi L, Swedberg K,. Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy. Eur Heart J 2011; 32: 2507-2515.
28. Tavazzi L, Swedberg K, Komajda M, Bohm M, Borer JS, Lainscak M, Ford I,. Efficacy and safety of ivabradine in chronic heart failure across the age spectrum: insights from the SHIFT study. Eur J Heart Fail 2013; 15: 1296-1303.
29. La Rovere MT, Bigger JT, Jr., Marcus FI, Mortara A, Schwartz PJ,. Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infarction. ATRAMI (Autonomic Tone and Reflexes After Myocardial Infarction) Investigators. Lancet 1998; 351: 478-484.
30. Tendera M, Talajic M, Robertson M, Tardif JC, Ferrari R, Ford I, Steg PG, Fox K,. Safety of ivabradine in patients with coronary artery disease and left ventricular systolic dysfunction (from the BEAUTIFUL Holter Substudy). Am J Cardiol 2011; 107: 805-811.
31. Kurtoglu E, Balta S, Karakus Y, Yasar E, Cuglan B, Kaplan O, Gozubuyuk G,. Ivabradine improves heart rate variability in patients with nonischemic dilated cardiomyopathy. Arq Bras Cardiol 2014; 103: 308-314.
32. Milliez P, Messaoudi S, Nehme J, Rodriguez C, Samuel JL, Delcayre C,. Beneficial effects of delayed ivabradine treatment on cardiac anatomical and electrical remodeling in rat severe chronic heart failure. Am J Physiol Heart Circ Physiol 2009; 296: H435-H441.
33. Dedkov EI, Zheng W, Christensen LP, Weiss RM, Mahlberg-Gaudin F, Tomanek RJ,. Preservation of coronary reserve by ivabradine-induced reduction in heart rate in infarcted rats is associated with decrease in perivascular collagen. Am J Physiol Heart Circ Physiol 2007; 293: H590-H598.
34. Camm AJ, Le Heyzey JY, Jern S, Savelieva I,. Ivabradine significantly increases heart rate variability compared with amlodipine in patients with chronic stable angina: a 3-month randomised double-blind controlled study. http://spo.escardio.org/abstract-book/presentation.aspx?id=49104. 2006; World Congress of Cardiology 2006, Barcelona, Spain (September 2-6, 2006). P4029. Abstract.
35. Reil JC, Robertson M, Ford I, Borer J, Komajda M, Swedberg K, Tavazzi L, Bohm M,. Impact of left bundle branch block on heart rate and its relationship to treatment with ivabradine in chronic heart failure. Eur J Heart Fail 2013; 15: 1044-1052.